• Home
  • Resources
  • CME
  • Project ECHO® Learning Series: Telementoring to Manage Immune-Related Adverse Events in Patients Receiving Cancer Immunotherapies

Project ECHO® Learning Series

Telementoring to Manage Immune-related Adverse Events
in Patients Receiving Cancer Immunotherapies

  • Registration:
  • CME Information or Content Source:
    This activity will be CME/CPE/CNE-certified
  • Event Sponsor(s):

    This activity is supported by an educational grant from Bristol Myers Squibb

  • Event Details:

    Program provided by Boston University (BU) and Association of Community Cancer Centers (ACCC)

  • Expires:
    May 16, 2023

Course Description

Could you benefit from expert advice on the optimal management of Immune-related Adverse Events (irAE)? If so, please join the Association of Community Cancer Centers and Boston University on the third Tuesday of every month from 3:00 – 4:00 PM ET for complimentary telementoring sessions. Each month we will cover a different topic, allowing you to receive guidance on clinical cases and have your questions answered by expert faculty. Registration is free and you will automatically be signed up for all sessions.

  • February 21, 2023
    Neurology
  • March 21, 2023
    Hepatology
  • April 18, 2023
    Dermatology
  • May 16, 2023
    Pulmonology

Learning Objectives

At the end of this educational activity, participants will be able to:

  • Apply evidence-based practices for the monitoring and management of irAE in patients receiving cancer immunotherapies
  • Improve coordination and communication with non-oncology specialists and with patients/caregivers to manage irAE in patients receiving cancer immunotherapies
  • Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies

We welcome you to submit unidentified clinical case scenarios for each of the tumor-board style discussions. Submission instructions will be available upon registration.

Target Audience

Oncologists, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, and other healthcare professionals involved in treating patients with cancer immunotherapies.